Skip to main content

Table 2 Overall control of blood pressure and LDL-C levels in all patients at baseline

From: Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial

Variables

Baseline

26 weeks

P-value

Systolic BP (mmHg), median (IQR)

125 (117–131)

130 (119–146)

< 0.001

Diastolic BP (mmHg), median (IQR)

78 (74–85)

81 (74–90)

0.002

Blood pressure < 140/90, n (%)

302 (81)

227 (61)

< 0.001

LDL-cholesterol, (mg/dL), median (IQR)

123 (96–150)

54 (43–69)

< 0.001

LDL-C < 55 mg/dl, n (%)

12 (3)

185 (51)

< 0.001

  1. BP, blood pressure; IQR, interquartile range, LDL-C, low-density lipoprotein-cholesterol